Cat.No. : CSC-RO0109 Host Cell: T47D
Size: >1x10^6 frozen cells/vial, 1 mL Stability: Stable in culture over a minimum of 10 passages
| Cat. No. | CSC-RO0109 |
| Description | T47D-p95HER2 cell line is a stably transfected cell line which expresses human p95HER2. |
| Target Gene | p95HER2 |
| Gene Species | Homo sapiens (Human) |
| Host Cell | T47D |
| Host Cell Species | Homo sapiens (Human) |
| Stability | Stable in culture over a minimum of 10 passages |
| Application | Drug screening and biological assays |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Size | >1x10^6 frozen cells/vial, 1 mL |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Researchers have increasingly focused on the role of the human epidermal growth factor receptor 2 (HER2) in breast cancer, particularly its isoforms, including the truncated carboxy-terminal fragment known as p95HER2. This variant has been linked to aggressive tumor behavior and resistance to standard therapies, making it a critical biomarker for the prognosis of HER2-positive breast cancer. The development of a specific monoclonal antibody (mAb) targeting the p95HER2 isoform, particularly the 611-CTF variant, highlights the importance of precise diagnostics in tailoring treatment. By utilizing a hybridoma technology, researchers successfully created an antibody, Oslo-2, that exhibits high specificity and affinity for 611-CTF-p95HER2, distinguishing it from full-length HER2 and other isoforms. This specificity is crucial, as p95HER2 is not expressed in normal tissues, making it an ideal target for therapeutic interventions.
Figure 1. The researchers selected polyclonal and monoclonal hybridomas via iQue screening, utilizing cell lines to assess p95HER2 binding efficacy. (Dorraji E, et al., 2022)
A: Human p95HER2 Stable Cell Line-T47D: This cell line is engineered to stably express the p95HER2 protein. This overexpression is achieved through genetic modifications, typically involving the insertion of a plasmid containing the gene encoding p95HER2 into the T47D cell genome. The plasmid is designed to integrate into the host cell's DNA and drive the expression of p95HER2 continuously.
A: Human p95HER2 Stable Cell Line-T47D: The T47D cell line utilized in the development of this product typically originates from a human breast cancer cell line. T47D cells were first isolated from a pleural effusion of a woman with ductal carcinoma. Since then, these cells have been extensively studied and propagated for various research purposes, including the development of stable cell lines expressing specific proteins like p95HER2.
A: Human p95HER2 Stable Cell Line-T47D: T47D cells are characterized by their luminal epithelial phenotype, resembling luminal breast cancer cells. They exhibit hormone receptor positivity, including estrogen and progesterone receptors, making them suitable for studying hormone-responsive breast cancer. Moreover, T47D cells are typically adherent in culture and grow as monolayers. They possess certain characteristics of differentiated mammary epithelial cells, providing a model system for studying various aspects of breast cancer biology and therapeutic responses.
A: The expression of p95HER2 in T47D cells can significantly influence their behavior and characteristics. p95HER2 is a truncated form of the HER2 receptor, known for its constitutive activation and involvement in signaling pathways related to cell proliferation, survival, and migration. Therefore, overexpression of p95HER2 may lead to enhanced cell proliferation, survival under adverse conditions, and increased migratory potential in T47D cells. Additionally, it can alter the response of T47D cells to various therapeutic agents targeting HER2 signaling.
A: Human p95HER2 Stable Cell Line-T47D: Yes, there are known interactions between p95HER2 and various signaling pathways in breast cancer cells. For instance, p95HER2 has been shown to crosstalk with the estrogen receptor (ER) pathway, influencing hormone responsiveness and endocrine therapy resistance in ER-positive breast cancers. Additionally, p95HER2 can interact with the PI3K/AKT/mTOR pathway, promoting cell survival and proliferation. These interactions highlight the complexity of signaling networks in breast cancer and the need for comprehensive understanding to develop effective targeted therapies.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
High expression of Human p95HER2 in T47D enables efficient detection and study of its functions.
This cell line offers stable and reliable experimental data, ensuring accuracy of results.
Suitable for prolonged experiments and research, supporting sustained scientific exploration.
Provides versatility for various experimental designs, meeting diverse research needs.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
